Literature DB >> 9035002

Catastrophic antiphospholipid antibody syndrome in pediatric systemic lupus erythematosus.

F Falcini1, G Taccetti, M Ermini, S Trapani, M Matucci Cerinic.   

Abstract

Catastrophic antiphospholipid antibody syndrome, reported in a minority of patients with circulating antiphospholipid antibodies, is characterized by widespread vascular occlusions. The term "catastrophic" has been used to describe the severity of symptomatology, sometimes leading to death. We describe a girl aged 11 years, fulfilling diagnostic criteria for systemic lupus erythematosus, with recurrent episodes of thromboembolic phenomena involving lung and skin, complicated with disseminated intravascular coagulation. Treatment with warfarin ultimately resulted in effective control of the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9035002

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.

Authors:  R Cervera; R A Asherson; M L Acevedo; J A Gómez-Puerta; G Espinosa; G De La Red; V Gil; M Ramos-Casals; M García-Carrasco; M Ingelmo; J Font
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 2.  Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome.

Authors:  Sonja Praprotnik; Dusan Ferluga; Alenka Vizjak; Anastazija Hvala; Tadej Avcin; Blaz Rozman
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  Catastrophic antiphospholipid antibody syndrome in a child with thrombotic microangiopathy.

Authors:  N Prasad; D Bhadauria; N Agarwal; A Gupta; P Gupta; M Jain; H Lal
Journal:  Indian J Nephrol       Date:  2012-07

4.  Catastrophic antiphospholipid syndrome in a 7-year-old girl.

Authors:  Jee Min Park; Jae Il Shin; Youn Ho Shin; Dong Soo Kim; Jae Seung Lee; Myung Joon Kim; Seung Koo Lee; Do Yun Lee
Journal:  Clin Rheumatol       Date:  2006-07-06       Impact factor: 3.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.